COE-1b

COE-1b is a preclinical-stage conjugated oligoelectrolyte (COE) derivative characterized by amidine side groups. It is being developed as a novel, broad-spectrum membrane-remodeling small molecule antibiotic to combat antimicrobial resistance (AMR), particularly targeting difficult-to-treat pathogens such as *Pseudomonas aeruginosa* and nontuberculous mycobacteria (NTM) like *Mycobacterium abscessus*. COE-1b acts by inserting into and perturbing the bacterial cell membrane, leading to membrane reorganization and cell death. It has demonstrated potent bactericidal activity, low propensity for resistance development, and robust synergistic efficacy when combined with frontline antibiotics (such as clarithromycin, fluoroquinolones, macrolides, aminoglycosides, and β-lactams) in various in vitro and in vivo animal models.

Other names

1bCOE 1bCOE1bCOE-1b